down arrow

Elanco Animal Health, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US28414H1032
USD
24.40
-0.51 (-2.05%)

Jan 23

NYS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

24.4024.83

52 Week

8.0225.29
Valuation
Technical
Day's Volume

CASH

1.14 M

Shareholding (Sep 2025)

FII

16.88%

Held by 169 FIIs

DII

14.1%

Held by 130 DIIs

Promoter

0.72%

How big is Elanco Animal Health, Inc.?

22-Jun-2025

As of Jun 18, Elanco Animal Health, Inc. has a market capitalization of $6.76 billion, with net sales of $4.43 billion and a net profit of $373 million over the latest four quarters. Shareholder's funds are reported at $6.10 billion, and total assets amount to $12.61 billion.

As of Jun 18, Elanco Animal Health, Inc. has a market capitalization of 6,759.36 million, categorizing it as a Mid Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 4,427.00 million, while the sum of net profit for the same period is 373.00 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 6,096.00 million, and total assets amount to 12,614.00 million.

View full answer

What does Elanco Animal Health, Inc. do?

22-Jun-2025

Elanco Animal Health, Inc. develops and markets products for companion and food animals, with net sales of $1.193 billion and a market cap of approximately $6.76 billion. Key metrics include a P/E ratio of 14.00 and a return on equity of 8.05%.

Overview:<BR>Elanco Animal Health, Inc. is an animal health company that develops, manufactures, and markets products for companion and food animals, operating within the Pharmaceuticals & Biotechnology industry and classified as a mid-cap company.<BR><BR>Financial Snapshot:<BR>Net Sales: 1,193 Million (Quarterly Results - Mar 2025) <BR>Net Profit: 67 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 6,759.36 Million (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 14.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.62 <BR>Return on Equity: 8.05% <BR>Price to Book: 1.06 <BR><BR>Contact Details:<BR>Address: 2500 Innovation Way N, GREENFIELD IN: 46140-9163 <BR>Website: https://www.elanco.com/

View full answer

Who are in the management team of Elanco Animal Health, Inc.?

22-Jun-2025

As of March 2022, the management team of Elanco Animal Health, Inc. includes R. David Hoover (Independent Chairman), Jeffrey Simmons (President & CEO), and several Independent Directors: William Doyle, Kapila Anand, John Bilbrey, Scott Ferguson, and Art Garcia. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Elanco Animal Health, Inc. includes the following individuals:<BR><BR>- Mr. R. David Hoover, who serves as the Independent Chairman of the Board.<BR>- Mr. Jeffrey Simmons, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. William Doyle, who is a Director.<BR>- Ms. Kapila Anand, who is an Independent Director.<BR>- Mr. John Bilbrey, who is also an Independent Director.<BR>- Mr. Scott Ferguson, who serves as an Independent Director.<BR>- Mr. Art Garcia, who is another Independent Director.<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

View full answer

Is Elanco Animal Health, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Elanco Animal Health, Inc. shows a mildly bullish trend with strong weekly indicators, outperforming the S&P 500 recently, but underperforming over the longer term.

As of 9 September 2025, the technical trend for Elanco Animal Health, Inc. has changed from bullish to mildly bullish. The weekly MACD and Bollinger Bands are bullish, while the monthly RSI is bearish, indicating mixed signals across different time frames. The daily moving averages are bullish, and the Dow Theory shows a mildly bullish stance on both weekly and monthly charts. <BR><BR>In terms of performance, Elanco has outperformed the S&P 500 in the past week (1.70% vs. 1.05%) and month (7.91% vs. 2.33%), but it has underperformed over longer periods, particularly in the 3-year (29.49% vs. 70.41%) and 5-year (-28.03% vs. 96.61%) comparisons. Overall, the current stance is mildly bullish, with key indicators showing strength in the weekly MACD and Bollinger Bands.

View full answer

Is Elanco Animal Health, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Elanco Animal Health, Inc. is considered overvalued with a valuation grade shift from very attractive to expensive, reflected by its lower P/E ratio compared to peers and poor long-term performance despite strong recent gains.

As of 17 October 2025, the valuation grade for Elanco Animal Health, Inc. has moved from very attractive to expensive, indicating a shift towards overvaluation. The company appears overvalued based on its current metrics, with a P/E ratio of 14, an EV to EBITDA of 12.07, and a PEG ratio of 0.03, which suggests limited growth relative to its price. In comparison, peers such as Illumina, Inc. and BioMarin Pharmaceutical, Inc. have P/E ratios of approximately 19.25 and 15.17, respectively, indicating that Elanco's valuation is less favorable in the context of its industry.<BR><BR>Despite strong recent performance, with a year-to-date return of 76.88% compared to the S&P 500's 13.30%, the long-term outlook appears less optimistic, as evidenced by a 5-year return of -32.09% against the S&P's 91.29%. This disparity in long-term performance further supports the conclusion that Elanco Animal Health, Inc. is currently overvalued.

View full answer

Compare Elanco Animal Health, Inc. with Similar Stocks

Bio-Techne Corp.BioMarin Pharmaceutical, Inc.Illumina, Inc.
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 12,074 Million (Small Cap)

stock-summary
P/E

14.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.52

stock-summary
Return on Equity

1.65%

stock-summary
Price to Book

1.79

Revenue and Profits:
Net Sales:
1,241 Million
(Quarterly Results - Jun 2025)
Net Profit:
11 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
12.08%
0%
12.08%
6 Months
62.45%
0%
62.45%
1 Year
102.32%
0%
102.32%
2 Years
65.76%
0%
65.76%
3 Years
84.43%
0%
84.43%
4 Years
-8.85%
0%
-8.85%
5 Years
-19.89%
0%
-19.89%

Elanco Animal Health, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Elanco Animal Health Hits New 52-Week High at $22.95

Elanco Animal Health Hits New 52-Week High at $22.95

Elanco Animal Health, Inc. has achieved a new 52-week high of USD 22.95, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. Over the past year, the company has seen a notable increase, outperforming the S&P 500, while maintaining a favorable P/E ratio and manageable debt levels.

Read full news article
Elanco Animal Health Hits New 52-Week High of $22.86

Elanco Animal Health Hits New 52-Week High of $22.86

Elanco Animal Health, Inc. achieved a new 52-week high of USD 22.86 on October 30, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has gained 23.74% over the past year, with a competitive P/E ratio of 14.00 and a manageable debt-to-equity ratio of 0.54.

Read full news article
Elanco Animal Health Hits New 52-Week High of $22.73

Elanco Animal Health Hits New 52-Week High of $22.73

Elanco Animal Health, Inc. achieved a new 52-week high of USD 22.73 on October 29, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a 23.85% increase over the past year, showcasing significant recovery and growth within its market.

Read full news article

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
9.86%
EBIT Growth (5y)
-0.48%
EBIT to Interest (avg)
0.90
Debt to EBITDA (avg)
5.95
Net Debt to Equity (avg)
0.62
Sales to Capital Employed (avg)
0.39
Tax Ratio
30.41%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
2.12%
ROE (avg)
2.44%

Valuation key factors

Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
1.09
EV to EBIT
45.24
EV to EBITDA
12.07
EV to Capital Employed
1.05
EV to Sales
2.44
PEG Ratio
0.03
Dividend Yield
NA
ROCE (Latest)
2.33%
ROE (Latest)
8.05%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 87 Schemes (68.26%)

Foreign Institutions

Held by 169 Foreign Institutions (16.88%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 4.02% vs 16.96% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -83.58% vs 937.50% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,241.00",
          "val2": "1,193.00",
          "chgp": "4.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "254.00",
          "val2": "282.00",
          "chgp": "-9.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "70.00",
          "val2": "53.00",
          "chgp": "32.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "8.00",
          "val2": "-24.00",
          "chgp": "133.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "11.00",
          "val2": "67.00",
          "chgp": "-83.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "68.50%",
          "val2": "101.40%",
          "chgp": "-3.29%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.50% vs 0.14% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 127.46% vs -1,478.21% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4,439.00",
          "val2": "4,417.00",
          "chgp": "0.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "913.00",
          "val2": "1,020.00",
          "chgp": "-10.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "339.00",
          "val2": "277.00",
          "chgp": "22.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-172.00",
          "val2": "-1,162.00",
          "chgp": "85.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "338.00",
          "val2": "-1,231.00",
          "chgp": "127.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "56.50%",
          "val2": "73.80%",
          "chgp": "-1.73%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary

Jun'25
Mar'25
Change(%)
Net Sales
1,241.00
1,193.00
4.02%
Operating Profit (PBDIT) excl Other Income
254.00
282.00
-9.93%
Interest
70.00
53.00
32.08%
Exceptional Items
8.00
-24.00
133.33%
Consolidate Net Profit
11.00
67.00
-83.58%
Operating Profit Margin (Excl OI)
68.50%
101.40%
-3.29%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 4.02% vs 16.96% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -83.58% vs 937.50% in Mar 2025

All Quarterly Resultsstock-summary

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
4,439.00
4,417.00
0.50%
Operating Profit (PBDIT) excl Other Income
913.00
1,020.00
-10.49%
Interest
339.00
277.00
22.38%
Exceptional Items
-172.00
-1,162.00
85.20%
Consolidate Net Profit
338.00
-1,231.00
127.46%
Operating Profit Margin (Excl OI)
56.50%
73.80%
-1.73%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.50% vs 0.14% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 127.46% vs -1,478.21% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Elanco Animal Health, Inc. stock-summary
stock-summary
Elanco Animal Health, Inc.
Pharmaceuticals & Biotechnology
Elanco Animal Health Incorporated is an animal health company that develops, manufactures and markets products for companion and food animals. The Company offers its products under four primary categories, such as Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. It provides a range of parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. It also offers a pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. It also provides treatments for otitis (ear infections), as well as cardiovascular and dermatology indications. Its portfolio in Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics. It also provides products in poultry and aquaculture production.
Company Coordinates stock-summary
Company Details
2500 Innovation Way N , GREENFIELD IN : 46140-9163
stock-summary
Tel:
stock-summary
https://www.elanco.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Download on App Store
Get it on Google Play
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."